trial

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

NCTId NCT00810667
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 124 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2010-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
124 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-11
Primary completion
2010-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lu AE58054

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

25 total
Liège, BelgiumLiège, BelgiumBordeaux, FranceBrumath, FranceNîmes, FranceToulouse, FranceDresden, GermanyHong Kong, Hong KongBrescia, ItalyNaples, ItalyBełchatów, PolandBialystok, Poland

Linked catalysts

1
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Pat — primary completion2010-01

Facts & assertions

4 sourced
Enrollment
124
Phase
PHASE2
Primary Completion Date
2010-01
Status
COMPLETED
relationships
The graph out of here
drug
Lu AE58054
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition
indication